Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Sylvia Asa, MD, PhD, FRCPC, FCAP, pathologist, Toronto General Hospital/Research Institute, professor, University of Toronto, discusses the ambiguity of certain subtypes of thyroid cancer. Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Asa says researchers are finding different mutations that make these different subtypes what they are. Some of these subtypes include TERT promoter mutations, as well as epigenetic changes such as alterations in the micro RNAs and epigenetic activation or silencing of genes. She says uncovering more information about these mutations and changes could aid in the creation of different therapies.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
November 13th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.
Read More
